Microbiome of human skin - its immunohomeostatic role and the role in pathogenesis of skin diseases



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the last decade new methods of metagenomic analysis allowed to obtain important data regarding the microbiome of human skin. The problem of colonization and secondary infection by pathogenic microbes is of special importance for allergic dermatoses that require topical immunosuppressive therapy. One of treatment options in this case could be topical multicomponent drugs that allow successful treatment of infectious complications of inflammatory dermatoses. But there are still a lot of blanks regarding both fundamental questions regarding human skin microbiome and practice aspects of treatment of skin diseases where it plays a pathogenetic role. This literature review systematizes and structures the accumulated data regarding the composition and the role of human skin microbiome in normal conditions and in various skin diseases as well as summarizes clinical data of use of combinational topical glucocorticosteroid drugs. Furthermore, some algorithms concerning the choice and optimization of topical treatment of secondary infected dermatoses are outlined.

Full Text

Restricted Access

About the authors

D D Petrunin

LEO Pharmaceutical Products LLC

Email: prof.preobrazhenskii@gmail.com

References

  1. Leung DIM. Staphylococcus aureus in atopic dermatitis. In: Reitamo S, Luger TA, Steinhoff M, eds. Textbook of atopic dermatitis. London: Informa Healthcare, 2008:59-68.
  2. Lubbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641-654. doi: 10.2165/00128071-200304090-00006.
  3. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9:244-253.
  4. Fyhrquist N, Salava A, Auvinen P, Lauerma A. Skin Biomes. Curr Allergy Asthma Rep. 2016;16:40. doi: 10.1007/s11882-016-0618-5.
  5. Chen YE, Tsao H. The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol. 2013;69:143-155. doi: 10.1016/j.jaad.2013.01.016.
  6. Nakamizo S, Egawa G, Honda T, Nakajima S, Belkaid Y, Kabashima K. Commensal bacteria and cutaneous immunity. Semin Immunopathol. 2015;37:73-80. doi: 10.1007/s00281-014-0452-6.
  7. Grice EA. The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous disease. Semin Cutan Med Surg. 2014;33:98-103. doi: 10.12788/j.sder.0087.
  8. Grice EA, Kong HH, Renaud G, Young AC, Bouffard GG, Blakesley RW et al. A diversity profile of the human skin microbiota. Genome Res. 2008;18:1043-1050. DOI: 10.1101/ gr.075549.107.
  9. Staley JT Konopka A. Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats. Annu Rev Microbiol. 1985;39:321-346. DOI: 10.1146/ annurev.micro.39.1.321.
  10. Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Biol Rev. 2004;68:669-685. doi: 10.1128/mmbr.69.1.195.2005.
  11. Pace NR. A molecular view of microbial diversity and the biosphere. Science. 1997;276:734-740. doi: 10.1126/sci-ence.276.5313.734.
  12. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA et al. The NIH human microbiome project. Genome Res. 2009;19:2317-2323. doi: 10.1101/gr.096651.109.
  13. Findley K, Oh J, Yang J, Conlan S, Deming C, Meyer JA et al. Topographic diversity of fungal and bacterial communities in human skin. Nature. 2013;498:367-370. DOI: 10.1038/ nature12171.
  14. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA. 2010;107:11971-11975. doi: 10.1073/pnas.1002601107.
  15. Capone KA, Dowd SE, Stamatas GN, Nikolovski J. Diversity of the human skin microbiome early in life. J Invest Dermatol. 2011;131:2026-2032. doi: 10.1038/jid.2011.168.
  16. Blaser MJ, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Estrada I et al. Distinct cutaneous bacterial assemblages in a sampling of South American Amerindians and US residents. ISME J. 2013;7:85-95. doi: 10.1038/ismej.2012.81.
  17. Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. Proc Natl Acad Sci USA. 2008;105:17994-17999. doi: 10.1073/pnas.0807920105.
  18. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009;326:1694-1697. doi: 10.1126/science.1177486.
  19. Marples RR, Downing DT, Kligman AM. Control of free fatty acids in human surface lipids by Corynebacterium acnes. J Invest Dermatol. 1971;56:127-131. doi: 10.1111/1523-1747. ep12260695.
  20. Gao Z, Perez-Perez GI, Chen Y, Blaser MJ. Quantitation of major human cutaneous bacterial and fungal populations. J. Clin. Microbiol. 2010;48:3575-3581. DOI: 10.1128/ jcm.00597-10.
  21. James AG, Austin CJ, Cox DS, Taylor D, Calvert R. Microbiological and biochemical origins of human axillary odour. FEMS Microbiol Ecol. 2013;83:527-540. doi: 10.1111/1574-6941.12054.
  22. Callewaert C, Kerckhof FM, Granitsiotis MS, Van Gele M, Van de Wiele T, Boon N. Characterization of Staphylococcus and Corynebacterium clusters in the human axillary region. PLoS One. 2013;8:e70538. doi: 10.1371/journal. pone.0070538.
  23. Chiller K, Selkin BA, Murakawa GJ. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc. 2001;6:170-174. doi: 10.1046/j.0022-202x.2001.00043.x.
  24. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30:16-34. DO I: 10.3109/08830185.2010.529976.
  25. Ermertcan AT, Öztürk F, Gündüz K. Toll-like receptors and skin. J Eur Acad Dermatol Venereol. 2011;25:997-1006. doi: 10.1111/j.1468-3083.2011.04049.x.
  26. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity. 2011;35:857-869. doi: 10.1016/j.immuni.2011.12.003.
  27. Strober W Epithelial cells pay a Toll for protection. Nature Med. 2004;10:898-900. doi: 10.1038/nm0904-898.
  28. Miller LS. Toll-like receptors in skin. Adv Dermatol. 2008;24:71-87. doi: 10.1016/j.yadr.2008.09.004.
  29. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med. 2009;15:1377-1382. doi: 10.1038/nm.2062.
  30. Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, McDowell A et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 2006;8:2195-2205. doi: 10.1016/j.micinf.2006.04.001.
  31. Webster GF. Skin Microecology. The Old and the New. Arch Dermatol. 2007;143:105-106. doi: 10.1001/archderm.143.1.105.
  32. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? Br J Dermatol. 2008;158:442-455. doi: 10.1111/j.1365-2133.2008.08437.x.
  33. Cogen AL, Yamasaki K, Sanchez KM, Dorschner RA, Lai Y, MacLeod DT et al. Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin. J Invest Dermatol. 2010;130:192-200. doi: 10.1038/jid.2009.243.
  34. Cogen AL, Yamasaki K, Muto J, Sanchez KM, Crotty Alexander L, Tanios J et al. Staphylococcus epidermidis antimicrobial delta-toxin (phenol-soluble modulin-gamma) cooperates with host antimicrobial peptides to kill group A streptococcus. PLoS One. 2010;5:e8557. doi: 10.1371/journal.pone.0008557.
  35. Gallo RL, Nakatsuji T Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol. 2011;131:1974-1980. doi: 10.1038/jid.2011.182.
  36. Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132:933-939. DOI: 10.1038/ jid.2011.417.
  37. Tognetti L, Martinelli C, Berti S, Hercogova J, Lotti T, Leoncini F, Moretti S. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012;26:931-941. doi: 10.1111/j.1468-3083.2011.04416.x.
  38. Белькова ЮА. Пиодермии в амбулаторной практике. Клиническая микробиология и антимикробная химиотерапия. 2005;(3):255-270 [Bel’kova YuA. Piodermii v ambulatornoi praktike. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2005;(3):255-270 (In Russ.)].
  39. Moreillon P, Que Y.A., Glauser M.P Staphylococcus aureus (Including Staphylococcal Toxic Shock). In: Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingston. 2005:2321-2351. DOI: 10.1016/ b978-0-443-06839-3.00195-8.
  40. Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med. 2005;202:209-215. doi: 10.1084/jem.20050846.
  41. Spaulding AR, Salgado-Pabôn W, Kohler PL, Horswill AR, Leung DYM, Schlievert PM. Staphylococcal and Streptococcal Superantigen Exotoxins. Clin Microbiol Rev. 2013;26:422-447. doi: 10.1128/cmr.00104-12.
  42. Peacock SJ, de Silva I, Lowy FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol. 2001;9:605-610. doi: 10.1016/s0966-842x(01)02254-5.
  43. Hale EM, Hinsdill RD. Biological activity of staphylococcin 162: bacteriocin from Staphylococcus aureus. Antimicrob Agents Chemother. 1975;7:74-81. doi: 10.1128/aac.7.1.74.
  44. Bisno AL, Stevens DL. Streptococcus pyogenes. In: Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingston. 2005:2321-2351. doi: 10.1016/b978-0-443-06839-3.00198-3.
  45. Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3:191-200. doi: 10.1016/s1473-3099(03)00576-0.
  46. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13:470-511. DOI: 10.1128/ cmr.13.3.470-511.2000.
  47. Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial-fungal interactions. Nature Rev Microbiol. 2010;8:340-349. doi: 10.1038/nrmicro2313.
  48. Cassone A, De Bernardis F, Santoni G. Anticandidal Immunity and Vaginitis: Novel Opportunities for Immune Intervention Infection and Immunity. 2007;75:4675-4686. DOI: 10.1128/ iai.00083-07.
  49. Wu L, Estrada O, Zaborina O, Bains M, Shen L, Kohler JE et al. Recognition of host immune activation by Pseudomonas aeruginosa. Science. 2005;309:774-777. DOI: 10.1126/ science.1112422.
  50. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacterspecies and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:49-56. doi: 10.1086/504477.
  51. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985;27:495-498. doi: 10.1128/aac.27.4.495.
  52. Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol. 2004;54:1212-1223. doi: 10.1111/j.1365-2958.2004.04349.x.
  53. Kerr JR, Taylor GW Rutman A, Hoiby N, Cole PJ, Wilson R. Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol. 1999;52:385-387. doi: 10.1136/jcp.52.5.385.
  54. Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688-697. doi: 10.1038/jid.2010.351.
  55. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Invest Dermatol Symp Proc. 2011;15:12-15. doi: 10.1038/jidsymp.2011.4.
  56. Whitfeld M, Gunasingam N, Leow LJ, Shirato K, Preda V. Staphylococcus epidermidis: a possible role in the pustules of rosacea. J Am Acad Dermatol. 2011;64:49-52. DOI: 10.1016/j. jaad.2009.12.036.
  57. Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol. 2013;69:1025-1032. doi: 10.1016/j.jaad.2013.08.006.
  58. Schommer NN, Gallo RL. Structure and function of the human skin microbiome. Trends Microbiol. 2013;21:660-668. doi: 10.1016/j.tim.2013.10.001.
  59. Pierard GE, Arrese JE, Pierard-Franchimont C, De Doncker P Prolonged effects of antidandruff shampoos - time to recurrence of Malassezia ovalis colonization of skin. Int J Cosmet Sci. 1997;19:111-117. doi: 10.1046/j.1467-2494.1997.171706.x.
  60. Leyden JJ, McGinley KJ, Kligman AM. Role of microorganisms in dandruff. Arch Dermatol. 1976;112:333-338. doi: 10.1001/archderm.112.3.333.
  61. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004;51:785-779. doi: 10.1016/j.jaad.2003.12.034.
  62. Mankowska-Wierzbicka D, Karczewski J, Dobrowolska-Zachwieja A, Adamski Z. The microbiome and dermatological diseases. Postepy Hig Med Dosw (Online). 2015;69:978-985.
  63. Gao Z, Tseng Ch, Strober BE, Pei Z, Blaser Mj. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;3:e2719. doi: 10.1371/journal. pone.0002719.
  64. Owen CM, Chalmers RJ, O’Sullivan T, Griffiths CE. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol. 2001;145:886-890. doi: 10.1046/j.1365-2133.2001.04504.x.
  65. Yamany T, Schwartz RA. Infectious eczematoid dermatitis: a comprehensive review. J Eur Acad Dermatol Venereol. 2015;29:203-208. doi: 10.1111/jdv. 12715.
  66. Хлебникова АН, Петрунин ДД, Молочков АВ. Учебно-методическое пособие «Липиды человеческого эпидермиса (фундаментальные сведения и клиническая имплементация)». М.: МОНИКИ, 2015 [Khlebnikova AN, Petrunin DD, Molochkov AV. Uchebno-metodicheskoe posobie «Lipidy chelovecheskogo epidermisa (fundamental’nye svedeniya i klinicheskaya implementatsiya)». M.: MONIKI, 2015 (In Russ.)].
  67. Schittek B. The antimicrobial skin barrier in patients with atopic dermatitis. Curr Probl Dermatol. 2011;41:54-67. doi: 10.1159/000323296.
  68. Lin YT, Wang CT, Chiang BL. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol. 2007;33:167-177. doi: 10.1007/s12016-007-0044-5.
  69. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. DOI: 10.1101/ gr.131029.111.
  70. Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature. 2010;465(7296):346-349. doi: 10.1038/nature09074.
  71. Ярилин АА. Иммунология: Учебник. М.: «ГЭОТАР-Медиа», 2010:749 [Yarilin AA. Immunologiya: Uchebnik. M.: «GEOTAR-Media», 2010:749 (In Russ.)].
  72. Spaulding AR, Salgado-Pabón W, Kohler PL, Horswill AR, Leung DY, Schlievert PM. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013;26:422-447. doi: 10.1128/cmr. 00104-12.
  73. Cardona ID, Cho SH, Leung DY. Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol. 2006;7:273-279. doi: 10.2165/00128071-200607050-00001.
  74. Solanki LS, Srivastava N, Singh S. Superantigens: a brief review with special emphasis on dermatologic diseases. Dermatol Online J. 2008;14:3.
  75. Macias ES, Pereira FA, Rietkerk W, Safai B. Superantigens in dermatology. J Am Acad Dermatol. 2011;64:455-472. doi: 10.1016/j.jaad.2010.03.044.
  76. Guedes A, Serra-Baldrich E, Alomar A. Role of superantigens in atopic dermatitis - a report by. Touch briefings. Germatology. 2008;3.
  77. Faergemann J. Atopic dermatitis and fungi. Clin Microbiol Rev. 2002;15:545-563. doi: 10.1111/j.1439-0507.2002. tb04591.x.
  78. Glatz M, Bosshard PP, Hoetzenecker W Schmid-Grendelmeier P The Role of Malassezia spp. in Atopic Dermatitis. J Clin Med. 2015;4:1217-1228. doi: 10.3390/jcm4061217.
  79. Атопический дерматит. Руководство для врачей. Под ред. Сергеева Ю.В. М.: «Медицина для всех», 2002 [Atopicheskii dermatit. Rukovodstvo dlya vrachei. Pod red. Sergeeva Yu.V. M.: «Meditsina dlya vsekh», 2002 (In Russ.)].
  80. Мачарадзе ДШ. Лечение инфекций кожи при атопическом дерматите у детей. Лечащий врач. 2006;(9):30-34 [Macharadze DSh. Lechenie infektsii kozhi pri atopicheskom dermatite u detei. Lechashchii vrach. 2006;(9):30-34 (In Russ.)].
  81. Petry V, Bessa GR, Poziomczyck CS, Oliveira CF, Weber Mb, Bonamigo RR, d’Azevedo PA. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012;87:729-734. doi: 10.1590/s0365-05962012000500010.
  82. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2000;44:1549-1555. DOI: 10.1128/ aac.44.6.1549-1555.2000.
  83. Chambers H, Deleo F. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-641. doi: 10.1038/nrmicro2200.
  84. Романов АВ, Чернов ЕА, Эйдельштейн МВ. Молекулярная эпидемиология внутрибольничных золотистых стафилококков в стационарах различных регионов России. Молекулярная медицина. 2013;(4):55-64 [Romanov AV, Chernov EA, Eidel’shtein MV. Molekulyarnaya epidemiologiya vnutribol’nichnykh zolotistykh stafilokokkov v statsionarakh razlichnykh regionov Rossii. Molekulyarnaya meditsina. 2013;(4):55-64 (In Russ.)].
  85. Мурашкин НН, Глузмин МИ, Скобликов НЭ, Бакулев АЛ, Материкин АИ, Глузмина ММ, Хотко АА. Роль метициллинрезистентных штаммов золотистого стафилококка в патогенезе тяжелых форм атопического дерматита в детском возрасте. Пути достижения ремиссии. Вестник дерматологии и венерологии. 2012;(1):66-74
  86. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann NY Acad Sci. 2006;1069:1-9. DOI: 10.1196/ annals.1351.001.
  87. Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60:125-136. doi: 10.1016/j.jaad.2008.07.058.
  88. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The Role of Malassezia spp. in Atopic Dermatitis. J Clin Med. 2015;4:1217-1228. doi: 10.3390/jcm4061217.
  89. Хлебникова АН, Марычева НВ. Особенности наружной терапии патологии кожи у больных сахарным диабетом. Клиническая дерматология и венерология. 2011;(6):52-58 [Khlebnikova AN, Marycheva NV. Osobennosti naruzhnoi terapii patologii kozhi u bol’nykh sakharnym diabetom. Klinicheskaya dermatologiya i venerologiya. 2011; (6):52-58 (In Russ.)].
  90. Мавлянова ШЗ. Клинико-иммунологическая характеристика кандидозной сенсибилизации у больных хроническими дерматозами. Вестник дерматологии и венерологии. 2001;(5);44-46 [Mavlyanova ShZ. Kliniko-immunologicheskaya kharakteristika kandidoznoi sensibilizatsii u bol’nykh khronicheskimi dermatozami. Vestnik dermatologii i venerologii. 2001;(5);44-46 (In Russ.)].
  91. Соколова ТВ, Мокроносова МА, Григорян СА. Особенности течения и ведения больных микробной экземой, ассоциированной с кандидозом кожи и слизистых оболочек. Российский журнал кожных и венерических болезней. 2007;1:13-20 [Sokolova TV, Mokronosova MA, Grigoryan SA. Osobennosti techeniya i vedeniya bol’nykh mikrobnoi ekzemoi, assotsiirovannoi s kandidozom kozhi i slizistykh obolochek. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2007;(1):13-20 (In Russ.)].
  92. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163:12-26. doi: 10.1111/j.1365-2133.2010.09743.x.
  93. Ewing CI, Ashcroft C, Gibbs AC, Jones GA, Connor PJ, David TJ. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol. 1998;138:1022-1029. doi: 10.1046/j.1365-2133.1998.02271.x.
  94. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155:680-687. doi: 10.1111/j.1365-2133.2006.07410.x.
  95. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001;108:651-652. doi: 10.1067/mai.2001.118598.
  96. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123:e808-814. doi: 10.1542/peds.2008-2217.
  97. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994;131:536-540. DOI: 10.1111/ j.1365-2133.1994.tb08556.x.
  98. Remitz A, Kyllönen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001;107:196-197. doi: 10.1067/mai.2001.112131.
  99. Leyden JJ, Kligman AM. The case for steroid-antibiotic combinations. Br J Dermatol. 1977;96:179-187. DOI: 10.1111/ j.1365-2133.1977.tb12541.x.
  100. Herbert S, Barry P, Novick RP. Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect Immun. 2001;69:2996-3003. doi: 10.1128/iai.69.5.2996-3003.2001.
  101. Sutton JB. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in facial impetigo. Curr Ther Res. 1992;51:673-678.
  102. Morley PAR, Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin. 1988;11:142-148. doi: 10.1185/03007998809110457.
  103. White DG, Collins PO, Rowsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice - a comparison of mupirocin with sodium fusidate. J Infect. 1989;18:221-229. doi: 10.1016/s0163-4453(89)80058-1.
  104. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol. 1989;20:1083-1087. doi: 10.1016/s0190-9622(89)70137-7.
  105. Jasuja K, Gupta SK, Arora DR, Gupta V. Bacteriology of primary pyodermas and comparative efficacy of topical application of mupirocin and sodium fusidate ointments in their treatment. Indian J Dermatol Venereol Leprol. 2001;67:132-134.
  106. Langdon CG, Mahapatra KS. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in acute skin sepsis. Curr Ther Res. 1990;48:174-179.
  107. Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N et al. TOC100224 Study Team. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215:331-340. doi: 10.1159/000107776.
  108. Cassels-Brown G. A comparative study of Fucidin ointment and Cicatrin cream in the treatment of impetigo. Br J Clin Pract. 1981;35:153-155.
  109. Von Daehne W, Godtfredsen WO, Rasmussen PR. Structure-activity relationships in fusidic acid-type antibiotics. Adv Appl Microbiol. 1979;25:95-146. doi: 10.1016/s0065-2164(08)70148-5.
  110. Белькова ЮА. Фузидовая кислота в современной клинической практике. Клиническая микробиология и антимикробная химиотерапия. 2001;(3):324-338 [Bel’kova YuA. Fuzidovaya kislota v sovremennoi klinicheskoi praktike. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2001;(3):324-338 (In Russ.)].
  111. Cundliffe E. The mode of action of fusidic acid. Biochem Biophys Res Commun. 1972;46:1794-1801. doi: 10.1016/0006-291x(72)90053-8.
  112. Borg A, Pavlov M, Ehrenberg M. Mechanism of fusidic acid inhibition of RRF- and EF-G-dependent splitting of the bacterial post-termination ribosome. Nucleic Acids Res. 2016;44:3264-3275. doi: 10.1093/nar/gkw178.
  113. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother. 1990;25:115. doi: 10.1093/jac/25. suppl_b.1.
  114. Stüttgen G, Bauer E. Penetration and permeation into human skin of fusidic acid in different galenical formulation. Arzneimittelforschung. 1988;38:730-735.
  115. Vickers CF. Percutaneous absorption of sodium fusidate and fusidic acid. Br J Dermatol. 1969;81:902-908. DOI: 10.1111/ j.1365-2133.1969.tb15972.x.
  116. Morris SD, Rycroft RJ, White IR, Wakelin SH, McFadden JP Comparative frequency of patch test reactions to topical antibiotics. Br J Dermatol. 2002;146:1047-1051. doi: 10.1046/j.1365-2133.2002.04662.x.
  117. Jappe U, Schnuch A, Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995-1999. Br J Dermatol. 2003;149:87-93. doi: 10.1046/j.1365-2133.2003.05290.x.
  118. Menday AP, Noble WC. Topical betamethasone/fusidic acid in eczema: efficacy against and emergence to resistance in Staphylococcus aureus. J Dermatol Treat. 2000;11:143-149. doi: 10.1080/09546630050517289.
  119. Schultz Larsen F, Simonsen L, Melgaard A, Wendicke K, Henriksen AS. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol. 2007;87:62-68. doi: 10.2340/00015555-0174.
  120. Инструкция по медицинскому применению препарата Пимафукорт (крем и мазь для наружного применения) П № 012689/01 и П № 012689/01 от 01.07.2009 [Pimafucort (cream and ointment for topical use) information leaflet. П № 012689/01 and П № 012689/01 as of 01.07.2009 (In Russ.)].
  121. Короткий НГ, Куликова ОД, Петрунин ДД. Дифференцированный подход к назначению комбинированных топических стероидов - минимизация риска нежелательных лекарственных реакций. Consilium Medicum прил. Дерматология. 2009;(3):3-6 [Korotkii NG, Kulikova OD, Petrunin DD. Differentsirovannyi podkhod k naznacheniyu kombinirovannykh topicheskikh steroidov - minimizatsiya riska nezhelatel’nykh lekarstvennykh reaktsii. Consilium Medicum pril. Dermatologiya. 2009;(3):3-6 (In Russ.)].
  122. Матушевская ЕВ, Свиршевская ЕВ. Эффективность и безопасность микронизированных лекарственных препаратов и их применение в дерматологической практике. Клиническая дерматология и венерология. 2015;(14):4-10 [Matushevskaya EV, Svirshevskaya EV. Effektivnost’ i bezopasnost’ mikronizirovannykh lekarstvennykh preparatov i ikh primenenie v dermatologicheskoi praktike. Klinicheskaya dermatologiya i venerologiya. 2015;(14):4-10 (In Russ.)]. doi: 10.17116/klinderma20151454-10.
  123. Кравченя СС, Игонина ИА, Бакулев АЛ. Комбинированная наружная терапия атопического дерматита. Клиническая дерматология и венерология. 2011;1:41-44 [Kravchenya SS, Igonina IA, Bakulev AL. Kombinirovannaya naruzhnaya terapiya atopicheskogo dermatita. Klinicheskaya dermatologiya i venerologiya. 2011;(1):41-44 (In Russ.)].
  124. Соколова ТЭ, Малярчук АП. Клиническое мышление - основа выбора рациональной тактики ведения больных микробной экземой. Consilium Medicum. прил. Дерматология. 2011;(2):6-13 [Sokolova TE, Malyarchuk AP Klinicheskoe myshlenie - osnova vybora ratsional’noi taktiki vedeniya bol’nykh mikrobnoi ekzemoi. Consilium Medicum. pril. Dermatologiya. 2011;(2):6-13 (In Russ.)].
  125. Малова ИО, Петрунин ДД. Натамицин - противогрибковое средство класса полиеновых макролидов с необычными свойствами. Вестник дерматологии и венерологии. 2015;(3):161-184 [Malova IO, Petrunin DD. Natamitsin - protivogribkovoe sredstvo klassa polienovykh makrolidov s neobychnymi svoistvami. Vestnik dermatologii i venerologii. 2015;(3):161-184 (In Russ.)]. doi: 10.25208/0042-4609-2015-0-3-161-184.
  126. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16:430-450. doi: 10.1128/cmr.16.3.430-450.2003.
  127. Aminoglycoside antibiotics: from chemical biology to drug discovery. Arya DP (ed.). Hoboken, John Wiley & Sons, Inc. 2007:327.

Copyright © Pharmarus Print Media, 2018



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies